ACLARIS THERAPEUTICS INC (ACRS)
US00461U1051 - Common Stock
Taking everything into account, ACRS scores 4 out of 10 in our fundamental rating. ACRS was compared to 193 industry peers in the Pharmaceuticals industry. ACRS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ACRS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ACRS had negative earnings in the past year.
ACRS had a negative operating cash flow in the past year.
In the past 5 years ACRS always reported negative net income.
In the past 5 years ACRS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -20.29%, ACRS is in the better half of the industry, outperforming 62.11% of the companies in the same industry.
With a decent Return On Equity value of -28.43%, ACRS is doing good in the industry, outperforming 67.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.29% | ||
| ROE | -28.43% | ||
| ROIC | N/A |
ROA(3y)-38.38%
ROA(5y)-70.27%
ROE(3y)-48.78%
ROE(5y)-102.5%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 53.53%, ACRS is in the better half of the industry, outperforming 62.63% of the companies in the same industry.
ACRS's Gross Margin has improved in the last couple of years.
ACRS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y26.47%
GM growth 5Y7.32%
2. Health
2.1 Basic Checks
ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACRS has been increased compared to 1 year ago.
Compared to 5 years ago, ACRS has more shares outstanding
There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -3.78, we must say that ACRS is in the distress zone and has some risk of bankruptcy.
ACRS's Altman-Z score of -3.78 is on the low side compared to the rest of the industry. ACRS is outperformed by 60.53% of its industry peers.
ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.78 |
ROIC/WACCN/A
WACC9.82%
2.3 Liquidity
ACRS has a Current Ratio of 7.03. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.03, ACRS is doing good in the industry, outperforming 75.26% of the companies in the same industry.
ACRS has a Quick Ratio of 7.03. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.03, ACRS is doing good in the industry, outperforming 76.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.03 | ||
| Quick Ratio | 7.03 |
3. Growth
3.1 Past
ACRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.29%, which is quite impressive.
The Revenue has grown by 26.36% in the past year. This is a very strong growth!
ACRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.42% yearly.
EPS 1Y (TTM)68.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.17%
Revenue 1Y (TTM)26.36%
Revenue growth 3Y68.95%
Revenue growth 5Y38.42%
Sales Q2Q%-53.18%
3.2 Future
ACRS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.42% yearly.
The Revenue is expected to grow by 15.95% on average over the next years. This is quite good.
EPS Next Y43.83%
EPS Next 2Y27.83%
EPS Next 3Y15.15%
EPS Next 5Y5.42%
Revenue Next Year-37.55%
Revenue Next 2Y-30.35%
Revenue Next 3Y-19.99%
Revenue Next 5Y15.95%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ACRS. In the last year negative earnings were reported.
Also next year ACRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ACRS's earnings are expected to grow with 15.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.83%
EPS Next 3Y15.15%
5. Dividend
5.1 Amount
ACRS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACLARIS THERAPEUTICS INC
NASDAQ:ACRS (12/23/2024, 1:04:37 PM)
2.99
+0.27 (+9.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners76.53%
Inst Owner Change-1.98%
Ins Owners2.48%
Ins Owner Change12.98%
Market Cap213.58M
Analysts83.08
Price Target7.75 (159.2%)
Short Float %3.62%
Short Ratio0.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-880.3%
Min EPS beat(2)-1788.67%
Max EPS beat(2)28.07%
EPS beat(4)3
Avg EPS beat(4)-412.16%
Min EPS beat(4)-1788.67%
Max EPS beat(4)94.31%
EPS beat(8)7
Avg EPS beat(8)-200.46%
EPS beat(12)11
Avg EPS beat(12)-128.13%
EPS beat(16)11
Avg EPS beat(16)-105.33%
Revenue beat(2)1
Avg Revenue beat(2)4.52%
Min Revenue beat(2)-40.15%
Max Revenue beat(2)49.19%
Revenue beat(4)3
Avg Revenue beat(4)123.29%
Min Revenue beat(4)-40.15%
Max Revenue beat(4)412.1%
Revenue beat(8)6
Avg Revenue beat(8)161.35%
Revenue beat(12)7
Avg Revenue beat(12)192.77%
Revenue beat(16)10
Avg Revenue beat(16)146.03%
PT rev (1m)390.32%
PT rev (3m)390.32%
EPS NQ rev (1m)-4.42%
EPS NQ rev (3m)13%
EPS NY rev (1m)-10.26%
EPS NY rev (3m)-16.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)15.15%
Revenue NY rev (1m)-19.9%
Revenue NY rev (3m)-19.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.89 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.64 | ||
| P/tB | 1.64 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.38
BVpS1.82
TBVpS1.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.29% | ||
| ROE | -28.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.53% | ||
| FCFM | N/A |
ROA(3y)-38.38%
ROA(5y)-70.27%
ROE(3y)-48.78%
ROE(5y)-102.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y26.47%
GM growth 5Y7.32%
F-Score6
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 63.13% | ||
| Cap/Sales | 2.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.03 | ||
| Quick Ratio | 7.03 | ||
| Altman-Z | -3.78 |
F-Score6
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)87.21%
Cap/Depr(5y)64.17%
Cap/Sales(3y)3.61%
Cap/Sales(5y)11.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.17%
EPS Next Y43.83%
EPS Next 2Y27.83%
EPS Next 3Y15.15%
EPS Next 5Y5.42%
Revenue 1Y (TTM)26.36%
Revenue growth 3Y68.95%
Revenue growth 5Y38.42%
Sales Q2Q%-53.18%
Revenue Next Year-37.55%
Revenue Next 2Y-30.35%
Revenue Next 3Y-19.99%
Revenue Next 5Y15.95%
EBIT growth 1Y65.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.12%
EBIT Next 3Y9.49%
EBIT Next 5YN/A
FCF growth 1Y72.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.68%
OCF growth 3YN/A
OCF growth 5YN/A